Gallium Ga 68-DOTATATE PET/CT in Diagnosing Patients With Metastatic Castration Resistant Prostate Cancer
| Status: | Recruiting |
|---|---|
| Conditions: | Prostate Cancer |
| Therapuetic Areas: | Oncology |
| Healthy: | No |
| Age Range: | 18 - Any |
| Updated: | 3/6/2019 |
| Start Date: | February 22, 2018 |
| End Date: | February 28, 2022 |
| Contact: | Mehmet Asim Bilen, MD |
| Email: | mbilen@emory.edu |
| Phone: | 404-778-3448 |
Molecular Imaging With Ga-68 DOTATATE PET to Investigate Neuroendocrine Differentiation in Prostate Cancer Patients
This pilot clinical trial studies how well gallium Ga 68-DOTATATE positron emission
tomography (PET)/computed tomography (CT) works in treating patients with castration
resistant prostate cancer that has spread to other placed in the body. Gallium Ga 68-DOTATATE
PET/CT may help doctors to identify those patients with early neuroendocrine
transdifferentiation and who are at greater risk for poor outcomes.
tomography (PET)/computed tomography (CT) works in treating patients with castration
resistant prostate cancer that has spread to other placed in the body. Gallium Ga 68-DOTATATE
PET/CT may help doctors to identify those patients with early neuroendocrine
transdifferentiation and who are at greater risk for poor outcomes.
PRIMARY OBJECTIVE:
Establish the feasibility of using gallium Ga 68-DOTATATE (68Ga-DOTATATE) PET as a predictive
imaging biomarker for neuroendocrine transdifferentiation in prostate cancer.
SECONDARY OBJECTIVE:
Correlate progression of disease with degree of uptake on 68Ga-DOTATATE PET examination.
OUTLINE:
Patients receive gallium Ga 68-DOTATATE intravenously (IV). Within 55-70 minutes, patients
undergo PET/CT.
After completion of study, patients are followed up for at least 1 year.
Establish the feasibility of using gallium Ga 68-DOTATATE (68Ga-DOTATATE) PET as a predictive
imaging biomarker for neuroendocrine transdifferentiation in prostate cancer.
SECONDARY OBJECTIVE:
Correlate progression of disease with degree of uptake on 68Ga-DOTATATE PET examination.
OUTLINE:
Patients receive gallium Ga 68-DOTATATE intravenously (IV). Within 55-70 minutes, patients
undergo PET/CT.
After completion of study, patients are followed up for at least 1 year.
Inclusion Criteria:
- Patients with metastatic castration resistant prostate carcinoma with skeletal,
visceral and/or nodal involvement
- Ability to lie still for PET scanning
- Patients must be able to provide written informed consent
Exclusion Criteria:
- Patients less than 18 years of age
- Patients without metastatic castration resistant prostate carcinoma with skeletal,
visceral and/or nodal involvement
- Inability to lie still for PET scanning
- Patients unable to provide written informed consent
We found this trial at
1
site
Click here to add this to my saved trials
